Overview

“…the development of Omnipaque set the gold standard for non-ionic imaging agents”3

Used since 1982 in everyday examinations or pioneering procedure, Omnipaque has been used extensively in over 100 countries, more than over 600 million procedures,2 examined in over 40 doctoral theses and 6,500 clinical studies, and subject to large safety surveillance studies on different continents.

The quality you want from contrast enhancement

  • Omnipaque has been unsurpassed by any low-osmolar contrast media (LOCM) for either diagnostic efficacy or tolerability at equi-attenuating doses in head-to-head trials4-18

Examples of clinical comparisons of other LOCM with Omnipaque

Comparator Procedure Superior efficacy to
Omnipaque at equi-
attenuating doses*
 iopamidol  myelography (n=363)4

 paediatric cardiac angiography (n=62)5

 NO

 NO
 iomeprol  intravenous urography (n=60)6

 myelography (n=83)7

 NO

 NO
 iopromide  aortography + visceral angiography (n=125)8

 excretory urography (n=200)9

 NO

 NO
 iobitridol  CT of the head (n=276)10

 hepatic CT (n=146)11

 NO

 NO
 ioversol  intravenous urography (n=80)12

 peripheral + visceral arteriography (n=60)13

 NO

 NO
 ioxaglate  lower limb phlebography (n=120)14

 angiography (n=80)15

 
 NO

 NO

*e.g. opacification, image quality, ability to make a diagnosis

A range of concentrations, volumes and pack sizes for optimal usage**

  • 140, 240, 300 and 350 mgI/mL19
  • 10, 20, 50, 100, 200 and 500 mL19

**Concentrations, volumes and packaging vary from country to country

References:
1. WHO Model List of Essential Medicines, 19th list, April 2015. Available at: http://www.who.int/medicines/publications/essentialmedicines/en/. Accessed on   17 March 2017.
2. Data on File, GE Healthcare, 2017.
3. Widmark JM. Proc (Bayl Univ Med Cent) 2007; 20: 408-17.
4. Lamb JT. Invest Radiol 1985; 20(Suppl.) S37–S43.
5. Rubin CME et al. Brit J Radiol 1987; 60: 133–5.
6. Harding JR et al. Brit J Radiol 1995; 68: 712–5.
7. Katayama H et al. Invest Radiol 2001; 36: 22–32.
8. Faykus MH et al. Invest Radiol 1994; 29 (Suppl.1): S98–S101.
9. Bischoff W. Fortschr Röntgenstr 1989; 128: 108–10.
10. Drouillard J et al. Acta Radiol 1996; 37 (Suppl.400): 56–61.
11. Legmann P et al. Eur Radiol 2001; 11: 2220–7.
12. Kaufman AJ et al. Urol Radiol 1990; 12: 56–60.
13. Cutcliff WB et al. Invest Radiol 1989; 24 (Suppl.1): S56–9.
14. Bertrand P et al. Acad Radiol 1995; 2: 683–6.
15. Krouwels MM et al. Eur J Radiol 1996; 22: 133–5.
16. Gomi T et al. Eur Radiol 2010; 20: 1631–5.
17. LaBounty TM et al. Am J Cardiol 2012; 109: 1594–9.
18. Dillman JR et al. Am J Roentgenol 2012; 198: 392–7.
19. Omnipaque Summary of Product Characteristics, May 2015.

JB7267/JB51616NL 02-2018

Usage

The versatility to match your imaging needs.

Omnipaque gives you reliability and choice

  • Indicated for intravenous, intra-arterial, body cavity, intrathecal and oral uses3
  • Approved for use in both adults and children3

Omnipaque is indicated for oral use:

Palatability

It has been shown that the administration of oral contrast medium is the least pleasant part of the patient computed tomography (CT) experience4

  • If a contrast medium for oral use is not unpleasant to taste, patients are more likely to be able to drink the volume required4
  • 81% of adult body CT patients, who expressed a preference, preferred Omnipaque over diatrizoate4

Omnipaque diluted with water came top in the taste test of various contrast media5

  • 98% of paediatric patients undergoing abdominal CT, many of whom were under 5, drank the required volume of diluted Omnipaque6

Usability

Hypertonic agents draw fluid from the plasma and interstitium into the bowel, resulting in progressive loss of radiocontrast through dilution as the agent travels through the gut5,6

  • Omnipaque provided better contrast density than sodium diatrizoate in adults with suspected intestinal obstruction7
  • Omnipaque is well suited for visualisation of intestinal loops and provided for good quality scans in children of all ages6,9,10

References:
1. WHO Model List of Essential Medicines, 19th list, April 2015. Available at: http://www.who.int/medicines/publications/essentialmedicines/en/. Accessed on   17 March 2017.
2. Data on File, GE Healthcare, 2017.
3. Omnipaque Summary of Product Characteristics, June 2016.
4. McNamara M et al. Am J Roentgenol May 2015; 195: 1137–41.
5. Diederichs G et al. Fortschr Röntgenstr 2007; 179: 1061–7.
6. Smevik B, Westvik J. Acta Radiol 1990; 31: 601–4.
7. Jobling C et al. Eur Radiol 1999; 9: 706–10.
8. Stordahl A et al. Acta Radiol 1988; 29: 53–6.
9. Stake G, Smevik B. In: Kaufmann HJ, ed. Contrast Media in Child Radiology. Basel, Switzerland: Karger; 1986; 107–9.
10. Smevik B, Stake G. In: Kaufmann HJ, ed. Contrast Media in Child Radiology. Basel, Switzerland: Karger; 1986; 79–80.

JB7267/JB51616NL 02-2018

Packaging

The packaging for workplace safety and efficiency*

Omnipaque’s unique +PLUSPAKTM packaging enhances user handling and workplace safety.

+PLUSPAKTM has no sharp alloy ring pull

  • Easy-open polypropylene ring pull avoids cuts from sharp metal edges3
  • Packaging removes risk of injuries from glass breakages3

+PLUSPAKTM has efficient labelling

  • Important information is repeated upside down for dual-direction reading
  • Colour-coded for concentration for easy recognition

+PLUSPAKTM reduces costs and environmental impact

  • Less storage space, lower disposal costs, reduced environmental impact3,4

*Concentrations, volumes and packaging vary from country to country

References:
1. WHO Model List of Essential Medicines, 19th list, April 2015. Available at: http://www.who.int/medicines/publications/essentialmedicines/en/. Accessed on   17 March 2017.
2. Data on File, GE Healthcare, 2017.
3. Gricar J et al. Radiol Manage 2007; SEP/OCT: 34–42.
4. Marshall G. Radiography 2008; 14: 128-34.

JB7167/JB51618NL 02-2018

Prescribing Information


Bijwerkingen rapporteren

Beroepsbeoefenaren in de gezondheidszorg worden verzocht alle vermoedelijke bijwerkingen te melden via: Nederlands Bijwerkingen Centrum Lareb, website: www.lareb.nl. Bijwerkingen kunnen ook direct worden gerapporteerd aan GE Healthcare B.V.


JB56491NL 03-2018